Clinical Trial

Investigating the Effects of Cannabidiol on Social Anxiety Disorder

Study acronym: CAN-SAD
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-05 -> 2027-05 2026-08-12
minor Completion pushed: 2026-09 -> 2027-05 2026-08-12
Trial Details
NCT Number NCT05649059
Lead Sponsor Massachusetts Institute of Technology
Collaborators: Massachusetts General Hospital
Conditions Phobia, Social
Enrollment 50 participants
Start Date 2025-07-10
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-11